Day One Biopharma Expands into Cancer Biotech with Acquisition of ADCs, Investing $55M for Phase 1-Ready Drug
Day One Biopharmaceuticals, a recently FDA-approved commercial-stage company, is expanding its pipeline by acquiring rights to a novel drug from MabCare Therapeutics. The drug, now renamed DAY301, targets protein-tyrosine kinase 7 (PTK7), which is found in certain cancer cells and pediatric cancers. This drug candidate could potentially compete with a similar drug from Genmab, acquired […]